CONTINUE TO SITE

OR WAIT null SECS

- About Us
- Advertise
- Contact Us
- Editorial Info
- Editorial Contacts
- Editorial Advisory Board
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions

© 2021 MJH Life Sciences^{™} and Pharmaceutical Technology. All rights reserved.

*The authors evaluated the manufacturing data of 40-mg tablets of furosemide, a potent diuretic.*

Furosemide is a potent loop diuretic used in the treatment of edematous states associated with cardiac, renal, and hepatic failure and for the treatment of hypertension. Complications, such as erratic systemic drug availability from the oral route of administration and from unpredictable responses to a given dosage, appear frequently. Furosemide's exact mechanism of action is not fully understood, but the drug is believed to act at the luminal surface of the ascending limb of the loop of Henle by inhibiting the active reabsorption of chloride ions. The response to a given dosage is modulated by the individual's fluid and electrolyte balance (1). Constant biopharmaceutical quality of furosemide tablets is therefore imperative to minimize undesirable *in vivo* variability.

Regulatory agencies around the world require proof of product consistency and a high degree of assurance that a product will meet all specifications (2–4). Thus, process evaluations need to follow scientific and statistical rationales. Simple test comparisons might not be sufficient. FDA strongly emphasizes that the pharmaceutical industry must understand process variation, including all sources and degrees of variation, and ultimately the effect of variation on product attributes (5). Furthermore, FDA guidance states that these data should be collected from the process-design stage through final-product manufacturing. This recommendation is a clear shift toward a product life-cycle approach including quality by design (5).

The adoption of statistical tools to evaluate data from an existing process can expose variability that might reveal that this process is not robust. On the other hand, a non-optimized process that is on its target value might be modified to improve productivity or increase robustness. Process variability can easily be revealed using control charts and statistical analysis.

Figure 1: Sampling scheme of the bin blender. (ALL FIGURES ARE COURTESY OF THE AUTHORS)

A prerequisite for process evaluation is the determination of the analytical method's variability. This determination can be accomplished using repeatability and reproducibility (RR) studies. *Repeatability,* sometimes called "equipment variation," is the ability of the measurement system to provide consistent readings when used by a single technician or operator. *Reproducibility,* sometimes referred to as "appraiser variation," is the ability to achieve consistent results for multiple operators. In general, an interval of 10% < %RR < 30% is considered adequate (6).

Figure 2: Control chart for individual (I), move range (MR), and standard deviation (StDev). The subgroup size was 10 (I-MR-R/S) for furosemide content in the powder mixture. LCL is lower control limit, S is standard deviation, UCL is upper control limit, and X is individual values.

Current FDA guidance embraces a risk-based approach, and the International Conference on Harmonization's *Pharmaceutical Quality Systems* recommends continuous improvement of the process performance and product quality (7–9). Statistical tools can enhance process understanding and foster innovative approaches to process validation and pharmaceutical development (5, 10). Among the statistical tools, the process-capability indices (i.e., Cp and Cpk) measure the process's ability to manufacture products that meet specifications and requirements. These indices greatly simplify the management of statistically controlled processes and have been used with the fundamental assumptions that the data are distributed normally, that the process is stable, and that its variability is known (6). The goal of the data evaluation was to assess the potential process capability index (i.e., Cp) and the actual process capability index (i.e., Cpk) using the content homogeneity of the powder mixture, tablet weight, dosage-unit uniformity, and dissolution behavior of 40-mg furosemide tablets.

Table I: Furosemide content in the powder blend.

**Materials**

Furosemide was supplied by Alcon Biosciences. Crospovidone was provided by ISP. Lactose monohydrate was purchased from Doremus. Talc was supplied by Indukern, and magnesium stearate by Inbra. The authors bought pregelatinized starch from Colorcon and maize starch from Cargill. Purified water was supplied by Prati-Donaduzzi. All the materials were of Brazilian Pharmacopoeia grade, as stated by the suppliers.

Table II: Values of the AndersonâDarling statistics (AD) and p-values performed for powder mixture conformity, uniformity of dosage units, and % released.

**Methods**

** Manufacturing process of 40-mg furosemide tablets. **Three consecutive 380-kg batches of 40-mg furosemide tablets were manufactured by wet granulation. The powders were mixed in a bin blender (VZD-400, Vanguard) for 20 min. at 18 rpm (see Figure 1). Next, powders were sieved through a 0.5-mm sieve and loaded into the high-shear mixer (MIC-P, Comasa, Buenos Aires). The granulation liquid was then sprayed tangentially into the moving powder mixture using a pneumatic atomizer at 1.0 bar atomizing air pressure and a speed of 80 rpm. The powder was mixed for 5 min. before the granulation was started. The spray rate was 40 g/min. The granules passed through a 2.5-mm sieve, dried at 50 ±3 °C in an oven for 24 h, passed through a 1.25-mm screen, and finally lubricated with magnesium stearate. The compression was performed employing a 50-station double rotary tableting machine (2000/50, Lawes, São Paulo). The speed was kept constant at 75,000 tablets/h. The Lawes tableting machine was dedicated equipment to produce furosemide tablets only.

Table III: Estimated variance component for furosemide content in the powder blend.

** Furosemide assay by ultraviolet-visible spectrophotometer. **The assays were performed in duplicate according to the

Figure 3: Capability analysis of the content (mg) of furosemide in the powder mixture. CL is control level, CP is process capability, Cpk is process-capability index, CPL is process capability relative to lower specification limit, CPU is process capability relative to upper specification limit, LSL is lower specification limit, PPM is parts per million, StDev is standard deviation, and USL is upper specification limit.

** Dissolution of furosemide tablets. **The dissolution test of furosemide tablets from the different batches (i.e., at the beginning, in the middle, and at the end of the process) was carried out in triplicate using

Figure 4: Control charts of individual and moving range (MR) of the individual tablet weights (mg) for the left and right sides of the tableting machine. LCL is lower control limit, LSL is lower specification limit, UCL is upper control limit, USL is upper specification limit, and X is individual value.

** Sampling plan and statistical analysis. **The sampling plan included the collection of 10 g of the powder mixture in 10 specific locations (see Figure 1). For the tablets, a minimum of 200 units on the right and left side of the double rotary tableting machine were collected. The uniformity of dosage units of furosemide was calculated using 30 tablets per batch (i.e., 10 tablets in the beginning, 10 in the middle, and 10 at the end of the tableting process). For the dissolution test, a total of six tablets for each batch—at the beginning, in the middle, and at the end of the process—were analyzed. The statistical analysis of the three consecutive batches was evaluated by using Minitab software, version 15 (Minitab, State College, PA).

Table IV: Tablet weights (mg) for left and right sides of the tableting machine for the three batches.

The process stability was evaluated using individual and moving-range charts as well as standard-deviation charts (I-MR-R/S), considering a subgroup size of 10. The normal distribution was evaluated by the Anderson–Darling test. For non-normal distributions according to the Anderson–Darling test, the Box–Cox family of power transformations was used to obtain an approximate Gaussian distribution (13).

Figure 5: Capability analysis of the tablet weights for three batches. Cp is process capability, Cpk is process-capability index, CPL is process capability relative to lower specification limit, CPU is process capability relative to upper specification limit, LSL is lower specification limit, PPM is parts per million, StDev is standard deviation, USL is upper specification limit, and X is individual value.

The process capability indices were calculated when the analyzed parameter was normally distributed or when its distribution was close to the normal distribution (6, 14). The fully nested analysis of variance (ANOVA) was performed to estimate variance components for each response variable (i.e., mixture content, tablet weight, dosage-unit uniformity, and dissolution). All factors were assumed to be random. The mean comparison between the tablet weights from the two sides of the tableting machine was performed using one-way ANOVA.

Table V: Tablet weight of furosemide (mg) versus left and right side of the tableting machine.

**Results and discussion**

** Content of furosemide in the powder mixture. **The relative standard deviation of the method was 0.43%. Random 10-g samples of the mixed powder were taken from 10 places within the bin blender (see Figure 1). Table I shows the data of the three consecutive batches. The powder blends met the acceptance criteria and the specifications (90.0–110.0%). The control charts did not show a special cause of variation (see Figure 2). Considering the analysis of locations, the one-way ANOVA was used to test for differences among the locations (see Figure 1). The analysis revealed no statistical difference between the locations (

Table VI: Values of the uniformity of dosage units.

The *p* value for the Anderson–Darling normality test was 0.069 (> 0.05), indicating a normal distribution (see Table II). This test was developed to be especially sensitive to deviations from normality in the distribution tails. For capability analysis, the tails are the most critical part of the distribution (15). To understand process variation, the authors performed a fully nested ANOVA (see Table III). The result showed that 72.90% of the observed variation in the furosemide content resulted from a batch factor. Thus, to minimize the process variability, the causes of the variation among batches required further investigation.

Figure 6: Control chart for individual, move range (MR) and standard deviation (StDev). The subgroup size was 10 (I-MR-R/S) for the uniformity of dosage units. LCL is lower control limit, S is standard deviation, and UCL is upper control limit.

The indices of 2.19 and 2.23 for Cpk and Cp, respectively, revealed that this process is statistically centered and robust (see Figure 3). The estimated nonconformity for the powder mixing process was less than 1 ppm. Cp and Cpk indices equal or above 1.0 correspond to a satisfactory low proportion of nonconformity (16). However, for a good process under statistical control, Cpk should be greater than 1.5 (17).

Figure 7: Capability analysis of the uniformity of dosage units of furosemide tablets. Cp is process capability, Cpk is process-capability index, CL is control level, CPL is process capability relative to lower specification limit, CPU is process capability relative to upper specification limit, LSL is lower specification limit, PPM is parts per million, StDev is standard deviation, and USL is upper specification limit.

** Evaluation of the tablet weight. **Figure 4 shows the individual tablet weights for each batch taken from the left and right sides of the tablet machine. The tablet weight was chosen as a surrogate for the process stability of the compression step. As shown in Figure 4, the two values above and the five values below the control limits, among 1200 samples analyzed, cannot support the assumption that this process was unstable. The mean tablet weight was 164.22 ±4.25 mg. In addition, all values were within the specification limits. The lower specification limit (LSL) was 152 mg, and the upper specification limit (USL) was 177 mg (see Table IV). However, a few outliers can have a large influence on the process-capability indices, as evidenced in Figure 5. The process capability indices were 1.00 and 0.98 for Cp and Cpk, respectively, revealing a high proportion of nonconformity (2751.21 ppm). Although interbatch variability could have contributed to the results, further investigation to address the high nonconformity was needed. Issues that may cause weight variation are powder flow problems, improper die fill, and powder size distribution.

Table VII: Estimated variance component for uniformity of dosage units of furosemide.

In addition, a comparison of the tablet weights at the two sides of the tableting machine was performed (see Table V). The *p* value (one-way ANOVA) was 0.522, showing that the tablet weights for both sides did not differ significantly. The residuals plot indicated a normal distribution and the absence of special causes of variation. Similar results were reported in a study where a double-station Kilian tableting machine (IMA Kilian, Köln, Germany) was used to manufacture metamizol tablets (18).

Table VIII: Values of the % drug released using tablet dissolution of furosemide tablet at the beginning.

** Evaluation of the uniformity of dosage units. **Table VI shows the dosage-unit uniformity for each batch for three different time periods: the beginning, middle, and end of the process. No special causes of variability were observed in the control charts (see Figure 6). The

Figure 8: Control chart for individual, move range (MR), and standard deviation (StDev). The subgroup size was 18 (I-MR-R/S) for the % released using tablet dissolution. LCL is lower control limit, S is standard deviation, UCL is upper control limit, and X is individual value.

The estimated source of variance showed that 54.19% of the observed variability was within a sampling group, 27.83% resulted from the sampling time point, and 17.98% resulted from the batch (see Table VII). To optimize this manufacturing process, the causes of the variations among the batches and the statistically noncentered profile of this process should be investigated.

Figure 9: Capability analysis of % released using tablet dissolution. Cp is process capability, Cpk is process-capability index, CPL is process capability relative to lower specification limit, CPU is process capability relative to upper specification limit, LSL is lower specification limit, PPM is parts per million, StDev is standard deviation, and USL is upper specification limit.

** Evaluation of the dissolution of furosemide tablets. **The dissolution of furosemide tablets was evaluated for each batch at the beginning, the middle, and the end of the process (see Table VIII). Figure 8 indicates that the process stability was achieved because no special cause of variation was observed. The

Table IX: Estimated variance component for the % drug released using tablet dissolution of furosemide.

**Conclusion**

The statistical approach used in the process evaluation of the blending, tableting, dosage-unit uniformity, weight variation, and dissolution behavior led to better process understanding of the manufacturing process. The results showed that fully nested ANOVA is a powerful tool to identify sources of variability. The process capability indices helped the authors to understand process performance and the potential for process optimization. Although a limited number of batches were investigated, the statistical methods identified possible approaches for process improvement in the manufacturing of furosemide tablets.

**Túlia de Souza Botelho** is a student, **Vanessa Franco Tavares** is a student, **Cátia Panizzon Dal Curtivo** is a student, and **Nádia Araci Bou-Chacra*** is an assistant professor of pharmaceutics, all at the Faculty of Pharmaceutical Sciences, University of São Paulo, 580 Lineu Prestes Ave., Butantan, São Paulo, SP – Brazil 05508-900, chacra@usp.br. **Silvie Rosa Balzan Sarolli** is a quality-assurance employee, **Márcio Adriano Fernandes** is a quality-control employee, and **Carmen Maria Donaduzzi** is a research pharmacist, all at Prati-Donaduzzi. **Raimar Löbenberg** is an associate professor of pharmaceutics at the University of Alberta.

*To whom all correspondence should be addressed.

Submitted: Aug. 31, 2010. Accepted: Nov. 29, 2010.

**References**

1. L.L.B. Ponto and R.D. Schoenwald, *Clin. Pharmacokinet. ***18** (1), 460–471 (1990).

2. EMEA, *Note for Guidance on Process Validation* (London, Mar. 2001), www.ema.europa.eu/pdfs/human/qwp/084896en.pdf, accessed Dec. 4, 2009.

*3. PIC/S, Validation Master Plan Installation and Operational Qualification Non-Sterile Process Validation Cleaning Validation, (Geneva, Sept. 2007), *www.picscheme.org/publication.php, * accessed Dec. 4, 2009.*

*4. ANVISA, National Health Surveillance Agency, Resolution-RDC 17 Current Good Manufacturing Practices for Drugs (Brasília,, DF, 2010), *ftp://ftp.saude.sp.gov.br/ftpsessp/bibliote/informe_eletronico/2010/iels.abr.10/Iels73/U_RS-MS-ANVISA-RDC-17_160410.pdf, * accessed. Aug. 31, 2010.*

*5. FDA, Guidance for Industry: Process Validation: General Principles and Practices: Draft Guidance (Rockville, MD, Nov. 2008).*

*6. D. Montgomery, Introduction to Statistical Quality Control (John Wiley and Sons, New York, 5th ed. 2004), p. 776.*

*7. FDA, Pharmaceutical cGMP for the 21st Century: A Risk Based Approach.*

8. ICH, Q9: *Quality Risk Management* (Geneva, 2006).

9. ICH, Q10: *Pharmaceutical Quality System* (Geneva, 2007).

10. ICH, Q8(R1): *Pharmaceutical Development* (Geneva, 2008).

11. *Brazilian Pharmacopoeia, *4th ed. (Brazilian Pharmacopoeia, São Paulo, 2001), p. 152.1

12. *USP* 32–*NF* 27 (US Pharmacopeial Convention, Rockville, MD, 2009), p. 2085.

13. G.E.P. Box and D.R. Cox, *J. R. Stat. Soc. Series B Stat. Methodol. ***26** (2), 211–252 (1964).

14. A. Czarski, *Arch. Mater. Sci. Eng. ***34** (1), 39–42 (2008).

15. P. Noceti, J. Smith, and S. Hodges, *J. Forecast. ***22** (6), 447–455 (2003).

16. H.C. Lin and G.J. Sheen, *Qual. Eng. ***17** (1), 371–390 (2005).

17. T. Pyzdek and P.A. Keller, *The Six Sigma Handbook: A Complete Guide for Green Belts, Black Belts, and Managers at All Levels,* (McGraw-Hill, New York, 3rd ed., 2009).

18. A.L.A. Vissotto et al., *Pharm. Ind. ***70** (11), 1414–1421 (2008).

19. S.S. Pal, *Qual. Eng. ***17** (1), 77–85 (2005).

**Related Content:**